Wedbush Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $42

Benzinga Newsdesk www.benzinga.com Positive 72.1%

Neg 0% Neu 0% Pos 72.1%

Wedbush analyst David Nierengarten initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform rating and announces Price Target of $42.